Bristol-Myers Says European Committee Recommends Approval of Opdivo-Yervoy Combination Therapy for Colorectal Cancer

MT Newswires Live11-15 22:08

Bristol-Myers Squibb (BMY) said Friday that a European Medicines Agency committee has recommended the approval of Opdivo in combination with Yervoy for the first-line treatment of adult patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer.

Results from the CheckMate -8HW study demonstrated a reduction in risk of disease progression or death by 79% relative to chemotherapy in the patient population, the company said.

The recommendation by the Committee for Medicinal Products for Human Use will now be reviewed by the European Commission before a final decision is made, Bristol-Myers added.

Price: 54.52, Change: +0.20, Percent Change: +0.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment